In the STEP-1 trial of 1,961 adults (Wilding and colleagues, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021), participants on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight at 68 weeks, compared to 2.4 percent on placebo
Evening dosing aligns with the bodys natural growth hormone rhythm, as the largest secretion pulses normally occur during deep sleep
It is widely studied for its effects on tendon, ligament, and gastrointestinal healing, as well as its anti-inflammatory and neuroprotective actions
Anti-inflammatory gene regulation Inflammation is a double-edged phenomenon
MOTS-c + Wolverine Blend: High compatibility, recommended